JP2024540152A5 - - Google Patents

Info

Publication number
JP2024540152A5
JP2024540152A5 JP2024525557A JP2024525557A JP2024540152A5 JP 2024540152 A5 JP2024540152 A5 JP 2024540152A5 JP 2024525557 A JP2024525557 A JP 2024525557A JP 2024525557 A JP2024525557 A JP 2024525557A JP 2024540152 A5 JP2024540152 A5 JP 2024540152A5
Authority
JP
Japan
Prior art keywords
ctla
antibody
therapeutic agent
agent according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078875 external-priority patent/WO2023077069A1/en
Publication of JP2024540152A publication Critical patent/JP2024540152A/ja
Publication of JP2024540152A5 publication Critical patent/JP2024540152A5/ja
Pending legal-status Critical Current

Links

JP2024525557A 2021-10-29 2022-10-28 抗ctla-4抗体投与レジメン Pending JP2024540152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163273660P 2021-10-29 2021-10-29
US63/273,660 2021-10-29
PCT/US2022/078875 WO2023077069A1 (en) 2021-10-29 2022-10-28 Anti-ctla-4 antibody dosing regimens

Publications (2)

Publication Number Publication Date
JP2024540152A JP2024540152A (ja) 2024-10-31
JP2024540152A5 true JP2024540152A5 (cg-RX-API-DMAC7.html) 2025-11-07

Family

ID=86158833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525557A Pending JP2024540152A (ja) 2021-10-29 2022-10-28 抗ctla-4抗体投与レジメン

Country Status (10)

Country Link
US (1) US20260139052A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422685A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540152A (cg-RX-API-DMAC7.html)
KR (1) KR20240099187A (cg-RX-API-DMAC7.html)
CN (1) CN118176021A (cg-RX-API-DMAC7.html)
AU (1) AU2022377644A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234351A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024004429A (cg-RX-API-DMAC7.html)
TW (1) TW202325738A (cg-RX-API-DMAC7.html)
WO (1) WO2023077069A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024238912A1 (en) * 2023-05-17 2024-11-21 OncoC4, Inc. Ph-sensitive anti-ctla-4 antibodies and uses thereof
WO2026041780A2 (en) * 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568016A (en) * 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
AU2016370648B2 (en) 2015-12-15 2023-03-09 OncoC4, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
KR20260053359A (ko) 자궁내막암 치료를 위한 항-pd-l1 항체와 하나 이상의 화학요법제의 조합
Van Cutsem et al. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
JP2023502929A5 (cg-RX-API-DMAC7.html)
CN118267469A (zh) 治疗驱动基因阳性肺癌的联用药物组合物
US20250295765A1 (en) Drug combination for treating non-small cell lung cancer
JP2023502876A5 (cg-RX-API-DMAC7.html)
Kato et al. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
Kojima et al. Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
CN116370641A (zh) 用于治疗消化系统恶性肿瘤的联用药物
WO2025103377A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
TW201922273A (zh) 用於治療肝癌之組合物及方法
US20230338521A1 (en) Methods of treating cancer using a combination of a pd-1 antagonist, a chemoradiation therapy and a parp inhibitor
Vansteenkiste et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model
CN120437288A (zh) 治疗卵巢癌的药物组合
Ettrich et al. Nintedanib plus mFOLFOX6 as second‐line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo‐controlled, phase II TRICC‐C study (AIO‐KRK‐0111)
JP2024527974A (ja) 小細胞肺がんを治療する薬物の組み合わせ
Camera et al. MOMENTUM: a phase I trial investigating 2 schedules of capecitabine with aflibercept in patients with gastrointestinal and breast cancer
CN118176021A (zh) 抗ctla-4抗体给药方案
CN114159557A (zh) 一种治疗肿瘤疾病的联合用药组合物及应用
WO2024183818A1 (zh) 抗cd20抗体药物偶联物在制备治疗非霍奇金淋巴瘤的药物中的用途
Jones et al. A randomized phase II trial of oral Topotecan versus Docetaxel in the second-line treatment of non–small-cell lung cancer
CN112543637B (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途
Tran et al. Hoang-Quy Nguyen1, Khanh-Luan Tran2, Manh-Hung Vuong3
Adachi et al. Clinical Phase I Study of TAS102/Irinotecan/Bevacizumab Combination Therapy in Japanese Patients With Unresectable Metastatic Colorectal Cancer (mCRC)